PTC THERAPEUTICS ($PTCT) posted quarterly earnings results on Thursday, August 7th. The company reported earnings of -$0.83 per share, beating estimates of -$1.02 by $0.19. The company also reported revenue of $178,880,000, beating estimates of $174,382,668 by $4,497,332.
You can see Quiver Quantitative's $PTCT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PTC THERAPEUTICS Insider Trading Activity
PTC THERAPEUTICS insiders have traded $PTCT stock on the open market 37 times in the past 6 months. Of those trades, 0 have been purchases and 37 have been sales.
Here’s a breakdown of recent trading of $PTCT stock by insiders over the last 6 months:
- MARK ELLIOTT BOULDING (EXEC. VP AND CLO) has made 0 purchases and 12 sales selling 96,700 shares for an estimated $5,107,932.
- MATTHEW B. KLEIN (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 4 sales selling 21,335 shares for an estimated $1,082,748.
- ERIC PAUWELS (CHIEF BUSINESS OFFICER) has made 0 purchases and 7 sales selling 14,165 shares for an estimated $777,680.
- STEPHANIE OKEY sold 5,000 shares for an estimated $270,000
- PIERRE GRAVIER (CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 4,851 shares for an estimated $241,448.
- NEIL GREGORY ALMSTEAD (CHIEF TECHNICAL OPS OFFICER) has made 0 purchases and 4 sales selling 2,946 shares for an estimated $147,627.
- LEE SCOTT GOLDEN (EVP & CHIEF MEDICAL OFFICER) has made 0 purchases and 3 sales selling 2,654 shares for an estimated $130,159.
- CHRISTINE MARIE UTTER (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 2 sales selling 1,757 shares for an estimated $88,043.
- ALLAN STEVEN JACOBSON sold 1,230 shares for an estimated $63,369
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PTC THERAPEUTICS Hedge Fund Activity
We have seen 145 institutional investors add shares of PTC THERAPEUTICS stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAMBER CAPITAL MANAGEMENT LP removed 1,700,000 shares (-53.1%) from their portfolio in Q1 2025, for an estimated $86,632,000
- FMR LLC added 1,193,518 shares (+145.5%) to their portfolio in Q1 2025, for an estimated $60,821,677
- BLACKSTONE INC. removed 1,059,574 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $53,995,891
- ARMISTICE CAPITAL, LLC removed 943,157 shares (-14.8%) from their portfolio in Q1 2025, for an estimated $48,063,280
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 790,450 shares (-95.6%) from their portfolio in Q1 2025, for an estimated $40,281,332
- MARSHALL WACE, LLP added 741,002 shares (+inf%) to their portfolio in Q1 2025, for an estimated $37,761,461
- CITADEL ADVISORS LLC added 709,606 shares (+154.9%) to their portfolio in Q1 2025, for an estimated $36,161,521
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PTC THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $PTCT in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 07/29/2025
- UBS issued a "Buy" rating on 07/29/2025
- B of A Securities issued a "Buy" rating on 07/29/2025
- Cantor Fitzgerald issued a "Overweight" rating on 07/29/2025
- Wells Fargo issued a "Overweight" rating on 07/29/2025
- JP Morgan issued a "Overweight" rating on 05/07/2025
- Baird issued a "Outperform" rating on 05/07/2025
To track analyst ratings and price targets for PTC THERAPEUTICS, check out Quiver Quantitative's $PTCT forecast page.
PTC THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $PTCT recently. We have seen 13 analysts offer price targets for $PTCT in the last 6 months, with a median target of $67.0.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $46.0 on 07/29/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $120.0 on 07/29/2025
- Tazeen Ahmad from B of A Securities set a target price of $84.0 on 07/29/2025
- Joon Lee from Truist Securities set a target price of $86.0 on 07/29/2025
- Colin Bristow from UBS set a target price of $80.0 on 07/29/2025
- Tiago Fauth from Wells Fargo set a target price of $78.0 on 07/29/2025
- Geoff Meacham from Citigroup set a target price of $50.0 on 07/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
